The efficacy and safety of trifluridine/tipiracil (FTD/TPI) for third-line treatment of metastatic colorectal cancer have been demonstrated. The authors present the Turkish analysis of the PRECONNECT study. An international, multicenter, single-arm, open-label, phase IIIb trial evaluating FTD/TPI in patients with ≥2 previous lines of chemotherapy for metastatic colorectal cancer was conducted. The primary end point was safety. In this Turkish cohort (n = 100; eight centers), the most frequent treatment-emergent adverse event was neutropenia (48%). Median progression-free survival was 3.0 months; disease control rate was 36%; quality of life remained stable. Outcomes with FTD/TPI in Turkey are consistent with previous studies and confirm the efficacy and safety of FTD/TPI treatment in the third-line setting. NCT03306394 (ClinicalTrials.gov).

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2022-0455DOI Listing

Publication Analysis

Top Keywords

metastatic colorectal
12
colorectal cancer
12
efficacy safety
8
safety
4
safety efficacy
4
efficacy trifluridine/tipiracil
4
trifluridine/tipiracil treated
4
treated metastatic
4
cancer preconnect
4
preconnect turkey
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!